ASH 2023 | CPX-351 plus venetoclax in patients with newly-diagnosed high-risk AML
Tapan Kadia
• 14 Dec 2023
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks through data presented on a study (NCT03629171) looking at the efficacy and safety of CPX-351 and venetoclax (CPX-ven) in relapsed/refractory (R/R) and newly-diagnosed acute myeloid leukemia (AML). This study showed that the combination is a feasible option for remission induction in this patient group, and is currently ongoing. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
